Rituximab or Cyclophosphamide in the Treatment of Membranous Nephropathy: The RI-CYCLO Randomized Trial
Authors: Scolari Francesco , Delbarba Elisa , Santoro Domenico , Gesualdo Loreto , Pani Antonello , Dallera Nadia , Mani Laila-Yasmin , Santostefano Marisa , Feriozzi Sandro , Quaglia Marco , Boscutti Giuliano , Ferrantelli Angelo , Marcantoni Carmelita , Passerini Patrizia , Magistroni Riccardo , Alberici Federico , Ghiggeri Gian Marco , Ponticelli Claudio , Ravani Pietro ,   for the RI-CYCLO Investigators
Published: March 2021

Significance Statement

A cyclic regimen of corticosteroid and cyclophosphamide is the first-line therapy for membranous nephropathy. Rituximab is superior to conservative treatment and noninferior to cyclosporine in inducing remission; it also may have a more favorable safety profile compared with cyclic therapy, but a head-to-head comparison of rituximab versus cyclic therapy is lacking. Using a multisite design, the authors designed a pilot randomized trial to obtain estimates of the effects of the two therapies and to assess the recruitment potential of a noninferiority trial. They found rituximab and cyclophosphamide may have comparable effects on disease remission and a similar short-term safety profile. These data suggest that, although rituximab may be a valid alternative to cyclic therapy for patients with membranous nephropathy, a head-to-head pragmatic comparison would require a large, global, noninferiority trial.

Background

A cyclic corticosteroid-cyclophosphamide regimen is the first-line therapy for membranous nephropathy. Compared with this regimen, rituximab therapy might have a more favorable safety profile, but a head-to-head comparison is lacking.

Methods

We randomly assigned 74 adults with membranous nephropathy and proteinuria >3.5 g/d to rituximab (1 g) on days 1 and 15, or a 6-month cyclic regimen with corticosteroids alternated with cyclophosphamide every other month. The primary outcome was complete remission of proteinuria at 12 months. Other outcomes included determination of complete or partial remission at 24 months and occurrence of adverse events.

Results

At 12 months, six of 37 patients (16%) randomized to rituximab and 12 of 37 patients (32%) randomized to the cyclic regimen experienced complete remission (odds ratio [OR], 0.4; 95% CI, 0.13 to 1.23); 23 of 37 (62%) receiving rituximab and 27 of 37 (73%) receiving the cyclic regimen had complete or partial remission (OR, 0.61; 95% CI, 0.23 to 1.63). At 24 months, the probabilities of complete and of complete or partial remission with rituximab were 0.42 (95% CI, 0.26 to 0.62) and 0.83 (95% CI, 0.65 to 0.95), respectively, and 0.43 (95% CI, 0.28 to 0.61) and 0.82 (95% CI, 0.68 to 0.93), respectively, with the cyclic regimen. Serious adverse events occurred in 19% of patients receiving rituximab and in 14% receiving the cyclic regimen.

Conclusions

This pilot trial found no signal of more benefit or less harm associated with rituximab versus a cyclic corticosteroid-cyclophosphamide regimen in the treatment of membranous nephropathy. A head-to-head, pragmatic comparison of the cyclic regimen versus rituximab may require a global noninferiority trial.

Clinical Trial registry name and registration number:

Rituximab versus Steroids and Cyclophosphamide in the Treatment of Idiopathic Membranous Nephropathy (RI-CYCLO), NCT03018535